Kilyos Assessoria, Cursos e Palestras (Kilyos Nutrition), São Paulo, SP 01311‑100, Brazil.
Department of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, SP 05508‑000, Brazil.
Int J Mol Med. 2021 Mar;47(3). doi: 10.3892/ijmm.2021.4844. Epub 2021 Jan 15.
Coronavirus disease 2019 (COVID‑19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), was identified in December, 2019 in Wuhan, China. Since then, it has continued to spread rapidly in numerous countries, while the search for effective therapeutic options persists. Coronaviruses, including SARS‑CoV‑2, are known to suppress and evade the antiviral responses of the host organism mediated by interferon (IFN), a family of cytokines that plays an important role in antiviral defenses associated with innate immunity, and has been used therapeutically for chronic viral diseases and cancer. On the other hand, OncoTherad, a safe and effective immunotherapeutic agent in the treatment of non‑muscle invasive bladder cancer (NMIBC), increases IFN signaling and has been shown to be a promising therapeutic approach for COVID‑19 in a case report that described the rapid recovery of a 78‑year‑old patient with NMIBC with comorbidities. The present review discusses the possible synergistic action of OncoTherad with vitamin D, zinc and glutamine, nutrients that have been shown to facilitate immune responses mediated by IFN signaling, as well as the potential of this combination as a therapeutic option for COVID‑19.
2019 年冠状病毒病（COVID-19）是由严重急性呼吸系统综合症冠状病毒 2 型（SARS-CoV-2）引起的，于 2019 年 12 月在中国武汉被发现。自那时以来，它在许多国家继续迅速传播，而寻找有效的治疗方法的努力仍在继续。众所周知，冠状病毒包括 SARS-CoV-2，会抑制和逃避宿主组织中干扰素（IFN）介导的抗病毒反应。干扰素是一种细胞因子家族，在与先天免疫相关的抗病毒防御中发挥着重要作用，并已被用于治疗慢性病毒疾病和癌症。另一方面，OncoTherad 是一种治疗非肌肉浸润性膀胱癌（NMIBC）的安全有效的免疫治疗药物，可增强 IFN 信号转导，在一份病例报告中被描述为 COVID-19 的有前途的治疗方法，该报告描述了一位 78 岁合并症患者的快速康复。本综述讨论了 OncoTherad 与维生素 D、锌和谷氨酰胺联合使用的可能协同作用，这些营养素已被证明可促进 IFN 信号转导介导的免疫反应，以及这种联合作为 COVID-19 治疗选择的潜力。
